NCT05707325View on ClinicalTrials.gov

Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

January 16, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

July 31, 2026

Conditions

CancerSolid TumorHematologic Malignancy

Interventions

DRUG

engineered red blood cell

engineered red blood cell

Trial Locations (1)

310014

RECRUITING

Zhejiang Provincial People'S Hospital, Hangzhou

All Listed Sponsors

lead

Westlake Therapeutics

INDUSTRY